Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

RIFABUTIN 150 MG CAPSULE

rifabutin
$9.4630per EA

Strength

150 mg/1

Manufacturer

Mylan Pharmaceuticals Inc.

NDC

59762135001

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

RIFABUTIN

Approval Type

Authorized Generic (NDA)

FDA Application

NDA050689

On Market Since

4/7/2014

Pharmacological Classes

Rifamycin Antimycobacterial
Rifamycins

Price History

1W

0.0%

1M

+3.1%

3M

+1.9%

6M

+8.4%

1Y

-4.5%

3Y

-12.1%

5Y

-20.9%

All

-28.4%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

RIFAMPIN 150 MG CAPSULE
Generic
24658080130•PuraCap Laboratories LLC
$0.5959
per EA
RIFAMPIN 150 MG CAPSULE
Generic
42806080130•Epic Pharma LLC
$0.5959
per EA
RIFAMPIN 150 MG CAPSULE
Generic
60687057521•American Health Packaging
$0.5959
per EA
RIFAMPIN 150 MG CAPSULE
Generic
68180065806•Lupin Pharmaceuticals Inc.
$0.5959
per EA
RIFAMPIN 300 MG CAPSULE
Generic
00904731561•Major Pharmaceuticals
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
24658080260•PuraCap Laboratories LLC
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
42806079901•Epic Pharma LLC
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
42806079930•Epic Pharma LLC
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
42806079960•Epic Pharma LLC
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
60687058601•American Health Packaging
$0.6805
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy